

# Community-Level PDMP Outcomes Module – Strategic Prevention Framework for Prescription Drugs (SPF Rx)

## Program Evaluation for Prevention (PEPC) – Cross-Site Evaluation

## ATTACHMENT 3

**Burden Statement:** This information is being collected to assist the Substance Abuse and Mental Health Services Administration (SAMHSA) for the purpose of monitoring the Strategic Prevention Framework for Prescription Drugs (SPF-Rx) grant program. This voluntary information collection will be used at an aggregate level to determine the reach, consistency, and quality of the SPF-Rx Program. Under the Privacy Act of 1974, any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0930-0377. Public reporting burden for this collection of information is estimated to average 1.25 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to SAMHSA Reports Clearance Officer, 5600 Fishers Ln, Room 15 E57B, Rockville, MD 20857.

# ATTACHMENT 3

## Contents

<b>Section</b>	<b>Page</b>
<b>1. Information and Directions.....</b>	<b>1</b>
<b>2. Opioid Prescribing Patterns and Prescriber Use of PDMP.....</b>	<b>2</b>
2.1 Opioid Prescribing Patterns (PDMP Data).....	3
2.2 Prescriber Use of PDMP (PDMP data).....	4

## ATTACHMENT 3

### 1. Information and Directions

In this Community-Level PDMP Outcomes Module, grantees report outcome data each year for their subrecipient communities. Grantee-level outcome data are reported in the Grantee-Level PDMP Outcomes Module.

**Grantee** is used to indicate the state/tribal entity/jurisdiction receiving the award from the Substance Abuse and Mental Health Services Administration (SAMHSA). Note that *grantee-level data* refers to the *entire* state (or tribal area or jurisdiction). **Subrecipient community** refers to the community entities that receive funds from the grantee to carry out Strategic Prevention Framework Prescription Drugs (SPF Rx) activities at the community level.

Data submission deadlines are January 15 each year. Report data for the prior calendar year. You will also be asked to provide baseline data for two years prior to the start of the grant, if available.

The PDMP Outcome Requirements at a Glance provides a summary of the reporting requirements. See the *PDMP Outcomes Module Guidance Manual* for more detailed instructions on how to report data and complete this module.

This module reports on opioid prescribing patterns and prescriber use of Prescription Drug Monitoring Program (PDMP) data, a key SPF Rx outcome.

**If you need assistance using the web-based data entry system, contact the Help Desk by leaving a message at (866)-245-8079 or sending an email to [pepc@rti.org](mailto:pepc@rti.org).** You can request assistance at any time, and someone will respond to you within 24 hours or the next business day.

### 2. Opioid Prescribing Patterns and Prescriber Use of PDMP

In this section, grantees will use PDMP data to report on opioid prescribing patterns and prescriber use of PDMP in their subrecipient communities during the 12-month

### **ATTACHMENT 3**

reporting period. Provide data for the closest available substate geographic unit (e.g., community, county, or district). Please see the guidance manual for further details on types of opioid prescriptions to be included.

#### **Data Source Time Frame (Start Date and End Date)**

Indicate the time frame during which data for this measure were collected. Enter the start date and end date for the time period of the data you are submitting.

Start Date: \_\_\_\_\_ (month/day/year)

End Date: \_\_\_\_\_ (month/day/year)

# ATTACHMENT 3

## 2.1 Opioid Prescribing Patterns (PDMP Data)

Here, you will enter the data for the PDMP indicators to measure opioid prescribing patterns in your subrecipient communities.

### PDMP Indicators for Opioid Prescribing Patterns in Subrecipient Community

Required Indicators	
Population (total number of residents in the geographic area for which you are reporting subrecipient community PDMP data)	
Total number of unique residents prescribed opioid analgesics	
Total number of opioid analgesic prescriptions	
Total number of high-dose opioid analgesic prescriptions (> 90 MME/day)	
Total number of opioid pills dispensed	
Average MME/day for all opioid prescriptions dispensed in this period	
Optional Indicators	
Percentage of patient prescription days with overlapping opioid and benzodiazepine prescriptions	
Number of multiple provider episodes (unique patients filling prescriptions from 5 or more prescribers and 5 or more pharmacies in a 6-month period)	
Percentage of patient prescription days with overlapping opioid prescriptions	
Total number of patients prescribed by a single provider >90 MME/day of opioids for 90 or more consecutive days	
Total number of prescribers who prescribed >90 MME/day of opioids for 90 or more consecutive days to any patients	

MME = morphine milligram equivalents

### Changes in PDMP Linking Algorithm

For the reporting year, did your PDMP change its algorithm for how it aggregates or links patients?

Yes (Explain) \_\_\_\_\_

No

## ATTACHMENT 3

### Data Comments

Please provide any additional information that would be useful in understanding the PDMP data you have provided related to opioid prescribing practices. Please note any changes that might have affected data quality for the reporting year and any changes to the algorithm to aggregate or link patients.

Data	Additional Information
PDMP indicators for opioid prescribing patterns	Free text

## 2.2 Prescriber Use of PDMP (PDMP data)

Here, you will enter the data to measure prescriber use of PDMP in your subrecipient communities. If relevant to your subrecipient communities, you also have the option to report on the number of pharmacists registered with the PDMP. Provide data for the closest available substate geographic unit (e.g., community, county, or district). Use the same unit you reported for item 2.1.

### Prescriber Use of PDMP in Subrecipient Community

Required Indicators for Prescribers	
Total number of prescribers in the subrecipient community who prescribed a schedule II–IV controlled substance during this annual reporting period, based on PDMP data (Denominator)	
Total number of prescribers in the subrecipient community who are registered with the PDMP	
Total number of prescribers (or their delegates) who queried the PDMP	
Total number of queries by prescribers (or their delegates) to PDMP	
Optional Indicator for Pharmacists/Dispensers	
Total number of pharmacists registered with the PDMP	
Total number of licensed pharmacists in the state (Denominator)	

## ATTACHMENT 3

### Data Comments

Please provide any additional information that would be useful in understanding the PDMP data you have provided related to prescriber use of PDMP. Please note any changes that might have affected data quality for the reporting year.

Data	Additional Information
Prescriber/dispenser use of PDMP	Free text